Drugs / autologous tumor lysate-pulsed DC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00068510 | Jun 2003 → Sep 2012 | central nervous system neoplasm | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous tumor lysate-pulsed DC | “Patients receive autologous tumor lysate-pulsed DC intradermally on days 0, 14, and 28 in the absence of unacceptable toxicity.” NCT00068510 ↗ |
| Action | Deplete | “Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.” NCT00068510 ↗ |
| Modality | Cell therapy | “Autologous dendritic cells (DC) are prepared from autologous PBMC exposed to sargramostim (GM-CSF) and interleukin-4 and pulsed with autologous tumor lysate.” NCT00068510 ↗ |